Supportive Oncology Services
Advancing oncology drug development and drug value through highly specialized expertise.
Supportive oncology expertise can be vital in drug development, offering innovative approaches to clinical teams to improve the management of disease symptoms and adverse events.
Hidden Costs of Drug Development and Life Cycle Management
Absence of expert supportive oncology within clinical study teams may lead to alternative management of adverse events, compromised treatment delivery, and higher healthcare costs. These challenges affect patient outcomes and treatment adherence.
Effective drug protocol development needs diverse expertise. Engagement with supportive oncology expertise can result in improved management of side effects, enhanced treatment delivery and improved drug marketability.
Better Outcomes with Supportive Oncology
Our team is led by Dr. Ann Berger, a pioneer in supportive oncology and palliative care. Our services offer the expertise needed to optimize clinical protocols, innovatively manage adverse events, and have the potential for improved patient outcomes within a larger healthcare ecosystem.
Our comprehensive supportive oncology insights into drug development programs may enhance treatment delivery and reduce healthcare costs.
Meet Dr. Ann Berger
Expertise That Makes a Difference
Dr. Ann Berger is an advanced practice oncology nurse, medical oncologist, researcher and supportive oncology and palliative care physician for over 30 years. Most recently, Dr. Berger was Chief of Pain and Palliative Care at the National Institutes of Health (NIH) clinical center for 24 years.
Dr. Berger has edited over 20 textbooks in supportive oncology including being the primary editor of the textbook, Principles and Practice in Palliative Care and Supportive Oncology, the first and main textbook in the field since 1998. The book is now in its 5th edition (2022).
Dr. Berger has co-authored hundreds of chapters, hundreds of peer-reviewed journal articles, including chapters in Devita and Rosenberg’s Principles and Practice of Oncology textbook since 2000 until present. Dr. Berger also spent over a decade developing a validated measurement instrument for psychosocial spiritual healing called the NIH HEALS.
Comprehensive Supportive Oncology Services
Innovative Oncology Drug Development Support Services
-
Leverage expert scientific input to enhance protocol development, optimize drug development, and improve oncology treatment delivery.
Scientific expertise in managing adverse events to optimize protocol and drug development.
Enhanced treatment delivery and improved patient outcomes.
-
Enrich your team's knowledge with targeted presentations, small group discussions, and fireside chats on palliative care, pain management, integrative modalities, and cutting-edge research.
Presentations, talks, roundtable discussions, and fireside chats on supportive oncology, palliative care, pain and symptom management, integrative modalities, and the latest research.
Training sessions to enhance team knowledge and skills in supportive oncology.
-
Develop comprehensive educational resources and guidelines for healthcare providers and patients, promoting better management of adverse events and improved patient education.
Optimizing letters for medical information teams.
Quality improvement initiatives with a deeper understanding of adverse events.
Optimizing guidelines on oncology drug-specific adverse event and symptom management.
Creation of physician pocket cards and patient education materials, including brochures, medical information letters, etc.
Support for RFPs.
By incorporating our supportive oncology expertise into drug development programs, your clinical teams can achieve:
Enhanced treatment delivery and treatment adherence
Enhanced management of adverse events
Enhanced patient recovery
Reduced burden within healthcare systems
In the rapidly evolving field of oncology, optimizing supportive care in drug development and post-marketing domains is crucial for improving patient outcomes and enhancing quality of life for patients with cancer.
Redefining Drug Development Standards in Oncology
Dr. Berger’s Supportive Oncology Services address critical challenges faced by biotech/pharmaceutical companies who are researching and developing important therapies for unmet medical needs. Our supportive oncology services have the potential to optimize patient outcomes throughout the lifecycle management process.
Optimized Protocols
Elevate your protocol standards with expert supportive oncology insights, enhancing adverse event management in clinical research and drug programs.
Innovative Solutions
Enhance patient outcomes and reduce healthcare costs with expert-derived supportive oncology protocols and comprehensive educational materials.
Customized Expertise
Address the intricate challenges of drug development with tailored, expert input, transforming the drug development ecosystem for better patient care and optimized treatment.
Partnership with
SHN Consulting LLC - Stacy Herb, PhD, MBA
Dr. Stacy Herb is a seasoned biopharmaceutical executive with over two decades of experience, adept at driving product development and strategy from concept inception to commercialization. Her expertise spans pre-clinical research, clinical development, regulatory affairs, and portfolio management across a diverse range of therapeutic modalities, including small molecules, biologics, and advanced cellular therapies. With a proven ability to build and lead high-performing teams, Dr. Herb has a successful track record of delivering innovative medicines to patients through IND filings, pivotal clinical trials, and global regulatory approvals. Her additional strengths in drug formulation and intellectual property management contribute to her comprehensive approach to drug development.
Meet Jackie Quan
Multi-organization, complex cancer research clinical alliances
“I help companies be better partners to the Groups of the National Clinical Trials Network (NCTN) as well as to the National Cancer Institute (NCI).”
Jackie Quan is an expert in various clinical trials business models. Jackie has extensive study management and teaming experience with investigator-sponsored trials (ISTs), cooperative group studies, consortia sponsored, foundation sponsored, company sponsored studies, and non-company sponsored research for health authority purpose.
Jackie has over 15 years of experience in various types of cooperative research and development agreements (CRADAs), applications, initiation, program management and alliances.
Shift your mindset
Precision medicine and rare patient populations demand massive amounts of collaboration, teaming, new clinical trials business models, new ways of thinking, as well as novel, yet practical, operational processes and procedures.